Dublin, Dec. 04, 2020 (GLOBE NEWSWIRE) -- The "Oncology Molecular Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global oncology molecular diagnostics market grew at a CAGR of around 12% during 2014-2019. Looking forward, the global oncology molecular diagnostics market to exhibit strong growth during the next five years.

Oncology molecular diagnostics identify the presence of cancer cells by analyzing their biological molecules. Several tests are performed on the blood, saliva, and tumor tissue samples for detecting and measuring specific genetic sequences in the DNA, RNA, and cell proteins.

Oncology molecular diagnostics help perform rapid analysis and provide detailed information that is further utilized in the personalized treatment of cancer. These diagnostics solutions find application in clinical and point-of-care (POC) testing for early detection of cancer. They are also used in blood banks to identify pathogens and infectious diseases present in the donated blood samples.

The rising prevalence of cancer on account of changing lifestyles, growing geriatric population, and the increasing trend of smoking represents one of the major factors impelling the global oncology molecular diagnostics market growth. Apart from this, the escalating demand for rapid and accurate diagnosis, along with advancements in next generation sequencing (NGS) techniques, is contributing to the growth of the market.

Furthermore, a rise in the number of individuals suffering from viral and bacterial infections and the increasing participation in blood donation campaigns is positively influencing the demand for oncology molecular diagnostics worldwide. However, due to the sudden outbreak of the coronavirus disease (COVID-19), several healthcare institutions are undertaking steps to mitigate the risk of the pandemic on cancer patients by reducing the number of medical appointments.

Moreover, regular screening for cancer patients has witnessed a decline due to the repurposing of diagnostics resources for providing COVID-19 testing and consequent reduction in oncology testing.

Key Questions Answered in This Report:

  • How has the global oncology molecular diagnostics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology molecular diagnostics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global oncology molecular diagnostics market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Oncology Molecular Diagnostics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Cancer Type
6.1 Breast Cancer
6.2 Prostate Cancer
6.3 Colorectal Cancer
6.4 Cervical Cancer
6.5 Liver Cancer
6.6 Lung Cancer
6.7 Blood Cancer
6.8 Others

7 Market Breakup by Product
7.1 Instruments
7.2 Reagents
7.3 Others

8 Market Breakup by Technology
8.1 Polymerase Chain Reaction (PCR)
8.2 In Situ Hybridization
8.3 Chips and Microarrays
8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.5 Mass Spectrometry
8.6 DNA and NGS Sequencing
8.7 Transcription Mediated Amplification (TMA)
8.8 Others

9 Market Breakup by End-User
9.1 Hospitals and Clinics
9.2 Reference Laboratories
9.3 Others

10 Market Breakup by Region

11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players

  • Agilent Technologies Inc.
  • Abbott Laboratories
  • Bayer AG
  • Becton, Dickenson and Company
  • Cepheid Inc. (Danaher Corporation)
  • F. Hoffmann-La Roche AG
  • Hologic Inc.
  • Qiagen N.V.
  • Siemens Healthcare
  • Sysmex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/elogga

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900